Search Results

By The ASCO Post Staff  / Monday, April 20, 2015 10:54 AM

AACR 2015: Pembrolizumab Shows Promise in Non–Small Cell Lung Cancer

The immunotherapy pembrolizumab (Keytruda) was found to be safe and yielded durable responses in patients with advanced, non–small cell lung cancer (NSCLC). Those with high levels of the protein PD-L1 in their tumors had better clinical outcomes, according to phase I KEYNOTE-001 clinical...